<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Edetate calcium disodium (calcium EDTA): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Edetate calcium disodium (calcium EDTA): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Edetate calcium disodium (calcium EDTA): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9401" href="/d/html/9401.html" rel="external">see "Edetate calcium disodium (calcium EDTA): Drug information"</a> and <a class="drug drug_patient" data-topicid="11359" href="/d/html/11359.html" rel="external">see "Edetate calcium disodium (calcium EDTA): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708725"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cerebral edema:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Edetate calcium disodium is capable of producing toxic effects that can be fatal. Lead encephalopathy is relatively rare in adults, but occurs more often in pediatric patients in whom it may be incipient and thus overlooked. The mortality rate in pediatric patients has been high. Patients with lead encephalopathy and cerebral edema may experience a lethal increase in intracranial pressure following, intravenous (IV) infusion; the intramuscular (IM) route is preferred for these patients. In cases where the IV route is necessary, avoid rapid infusion. The dosage schedule should be followed and at no time should the recommended daily dose be exceeded.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058251"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Lead Toxicity</span>;</li>
<li>
<span class="list-set-name">Chelating Agent, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F164149"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consultation with a clinical toxicologist, poison control center, or an expert in the treatment of heavy metal poisoning is highly recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b47c937b-9735-45ce-ac30-9f94ed987b08">Lead poisoning, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For the treatment of high blood lead levels (BLLs) in children, the CDC recommends chelation treatment when BLL &gt;45 mcg/dL (CDC 2002). The AAP recommends succimer for initial management in asymptomatic children when BLL &gt;45 mcg/dL and &lt;70 mcg/dL. Edetate CALCIUM disodium can be used in children allergic to succimer (AAP 2005; Chandran 2010). Combination therapy with edetate CALCIUM disodium and dimercaprol is recommended for use in children whose BLL ≥70 mcg/dL or in pediatric patients with lead encephalopathy (AAP 2005; AAP [Shenoi 2020]; Calello 2018). Depending upon the BLL, additional courses may be necessary; at least 2 to 4 days should elapse before repeat treatment is initiated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Blood lead levels 45 to &lt;70 mcg/dL and asymptomatic:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IM, IV: 1,000 mg/m<sup>2</sup>/day (~25 to 50 mg/kg/day) as either a once-daily continuous IV infusion (preferred) or as equally divided intermittent doses every 6 to 12 hours; treatment duration: 5 days; maximum daily dose: 1,000 mg/<b>day </b>(Calello 2018; Chandran 2010). <b> Note: </b>Although intermittent IV doses are an option, single dose infusion time (over 8 to 12 hours) and admixture volumes for each dose may preclude use in some patients.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b> Treatment courses may be repeated, but a 2-week interval between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment. High initial BLL (eg, &gt;100 mcg/dL) or presence of lead encephalopathy may indicate the need for more prompt retreatment (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Blood lead levels ≥70 mcg/dL or symptomatic lead poisoning (without encephalopathy): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IM, IV: 1,000 to 1,500 mg/m<sup>2</sup>/day <b>or</b> 25 to 75 mg/kg/day as either a once-daily continuous IV infusion (preferred) or as equally divided intermittent doses every 6 to 12 hours; begin treatment 4 hours after the first dimercaprol dose; treatment duration: 5 days; maximum daily dose: 1,000 mg/<b>day</b> in children; in adults, the maximum daily dose is 3,000 mg/<b>day</b> (AAP [Shenoi 2020]; Calello 2018; Chandran 2010; Howland 2018). <b>Note:</b> Although intermittent IV doses are an option, single dose infusion time (over 8 to 12 hours) and admixture volumes for each dose may preclude use in some patients.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Treatment courses may be repeated; for lower BLL (eg, &lt;70 mcg/dL), a 2-week interval between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment. High initial BLL (eg, &gt;100 mcg/dL) or presence of lead encephalopathy may indicate the need for more prompt retreatment (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lead encephalopathy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: <b></b>IM, IV: 1,500 mg/m<sup>2</sup>/day <b>or </b>50 to 75 mg/kg/day as either a once-daily continuous IV infusion (preferred) or as equally divided intermittent doses every 6 to 12 hours; treatment duration: 5 days; maximum daily dose: 1,000 mg/<b>day </b> in children; in adults, the maximum daily dose is 3,000 mg/<b>day</b>; treatment courses may be repeated (AAP [Shenoi 2020]; Calello 2018; Chandran 2010; Howland 2018). <b>Note:</b> Although intermittent IV doses are an option, single dose infusion time (over 8 to 12 hours) and admixture volumes for each dose may preclude use in some patients.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51107956"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: Dose should be reduced with preexisting mild renal disease. Limiting the daily dose to 1,000 mg in children and 2,000 mg in adults may decrease risk of nephrotoxicity, although larger doses may be needed in the treatment of lead encephalopathy (Howland 2018).</p></div>
<div class="block dohp drugH1Div" id="F51107957"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F164145"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9401" href="/d/html/9401.html" rel="external">see "Edetate calcium disodium (calcium EDTA): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad6c1520-f76f-4866-9ee2-58ecc5033ef3">Lead poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning:</b>
<b>Note:</b> Available guidelines recommend chelation therapy with blood lead levels (BLLs) &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated for most patients with BLLs &gt;80 mcg/dL and all patients with BLLs ≥100 mcg/dL and/or symptoms (CSTE 2013; Kosnett 2007). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptoms suggestive of encephalopathy or BLLs &gt;100 mcg/dL:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV: </b>1,500 mg/m<sup>2</sup>/day <b>or</b> 50 to 75 mg/kg/day for 5 days (maximum: 3,000 mg per day [Howland 2018]); administer as a continuous infusion <b>or </b>in 2 to 4 divided doses (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients who are also receiving dimercaprol, begin treatment with edetate CALCIUM disodium 4 hours after initiation of dimercaprol (ie, with the second dimercaprol dose) (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Encephalopathy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV:</b> 1,000 to 1,500 mg/m<sup>2</sup>/day <b>or</b> 25 to 75 mg/kg/day for 5 days (maximum: 3,000 mg per day [Howland 2018]); administer as a continuous infusion <b>or </b>in 2 to 4 divided doses (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients who are also receiving dimercaprol, begin treatment with edetate CALCIUM disodium 4 hours after initiation of dimercaprol (ie, with the second dimercaprol dose) (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Treatment courses may be repeated, but 2-week intervals between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment. High initial BLLs (eg, &gt;100 mcg/dL) or presence of lead encephalopathy may indicate the need for more prompt retreatment (Howland 2018); consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning is highly recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lead nephropathy:</i> An alternative dosing regimen that reflects the reduction in renal clearance and is based upon the serum creatinine is provided by the manufacturer; however, the decision to use chelation therapy in patients without elevated BLLs and symptoms should only be made in consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning. <b>Note:</b> The manufacturer recommends repeating the regimen monthly until BLLs are reduced to an acceptable level: <b>IM, IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">S<sub>cr</sub> 2 to 3 mg/dL: 500 mg/m<sup>2</sup> every 24 hours for 5 days.</p>
<p style="text-indent:-2em;margin-left:6em;">S<sub>cr</sub> 3 to 4 mg/dL: 500 mg/m<sup>2</sup> every 48 hours for 3 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">S<sub>cr</sub> &gt;4 mg/dL: 500 mg/m<sup>2</sup> once weekly.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991916"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dose should be reduced with preexisting mild renal disease. Limiting the daily dose to 2 g in adults may decrease risk of nephrotoxicity, although larger doses may be needed in the treatment of lead encephalopathy (Howland 2018).</p></div>
<div class="block doha drugH1Div" id="F51107972"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F164121"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia, ECG changes, hypotension, local thrombophlebitis (IV infusion when concentration &gt;5 mg/mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Chills, fatigue, headache, malaise, numbness, paresthesia</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Cheilosis, dermatitis, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Glycosuria, hypercalcemia, hypokalemia, iron deficiency (with chronic therapy), magnesium deficiency (with chronic therapy), polydipsia, zinc deficiency (with chronic therapy)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Anorexia, gastrointestinal irritation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Nephrosis, nephrotoxicity, occult blood in urine, proteinuria, urinary frequency, urinary urgency</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Anemia, bone marrow depression (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Decreased serum alkaline phosphatase, increased liver enzymes (mild)</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site (intramuscular)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia, tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Lacrimation</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Renal tubular necrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Nasal congestion, sneezing</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F164134"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Active renal disease or anuria; hepatitis</p></div>
<div class="block war drugH1Div" id="F164118"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Monitor for arrhythmias and ECG changes during IV therapy</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Edetate CALCIUM disodium is potentially nephrotoxic. Renal tubular acidosis and fatal nephrosis may occur, especially with high doses; do not exceed the recommended daily dose. If anuria, increasing proteinuria, or hematuria occurs during therapy, discontinue use. Minimize nephrotoxicity by providing adequate hydration, establishment of good urine output, avoidance of excessive doses, and limit continuous administration to ≤5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebral edema: <b>[US Boxed Warning]: Use with extreme caution in patients with lead encephalopathy and cerebral edema.</b> In these patients, IV infusion has been associated with a lethal increase in intracranial pressure; IM injection is preferred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment. Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended before initiating chelation therapy. Do not permit patients to re-enter the contaminated environment until lead abatement has been completed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; reduced dose recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Potential for name confusion: Exercise caution in the ordering, dispensing, and administration of this drug. Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na<sub>2</sub>EDTA) (not commercially available in the US or Canada). Fatal hypocalcemia may result if edetate disodium is used for the treatment of lead poisoning instead of edetate CALCIUM disodium (Baxter 2008). The CDC and FDA recommend that edetate disodium should never be used for chelation therapy (especially in children) (Mitka 2008). Death has occurred following the use of edetate disodium for chelation therapy in pediatric patients with autism (Baxter 2008).</p></div>
<div class="block foc drugH1Div" id="F164129"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F164114"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F58318435"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Edetate Calcium Disodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/5 mL (per mL): $1,558.71</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612666"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: For IM or IV use; IV is generally preferred; however, the IM route is preferred when cerebral edema is present.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion: Administer the daily dose as a diluted solution over 8 to 12 hours or continuously over 24 hours (Howland 2018). Avoid rapid infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">IM injection: Daily dose should be divided into 2 to 4 equal doses spaced 6 to 12 hours apart. Procaine hydrochloride or lidocaine may be added to the edetate CALCIUM disodium to minimize pain at injection site. Administer by deep IM injection. When used in conjunction with dimercaprol, inject into a separate site.</p></div>
<div class="block adm drugH1Div" id="F164131"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For IM or IV use; IV is generally preferred, however, the IM route is preferred when cerebral edema is present.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV</b> infusion: Administer the daily dose as a diluted solution over 8 to 12 hours or continuously over 24 hours (Howland 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">For <b>IM</b> injection: Daily dose should be divided into 2 to 4 equal doses (Calello 2018). Procaine hydrochloride or lidocaine may be added to the edetate CALCIUM disodium to minimize pain at injection site. Administer by deep IM injection. When used in conjunction with dimercaprol, inject into a separate site.</p></div>
<div class="block sts drugH1Div" id="F6151789"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 25°C (77°F); excursion permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes: </i>Guidelines suggest that at least 0.75 to 2.25 g of edetate CALCIUM disodium be stocked. Suggested amount is stated to be a sufficient quantity to treat one patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53566631"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of symptomatic acute and chronic lead poisoning [FDA approved pediatric patients (age not specified) and adults]</p></div>
<div class="block mst drugH1Div" id="F2932700"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">To avoid potentially serious errors, the abbreviation “EDTA” should <b>never</b> be used.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;">Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na<sub>2</sub>EDTA) (not commercially available in the U.S. or Canada). CDC recommends that edetate disodium should <b>never</b> be used for chelation therapy in children. Fatal hypocalcemia may result if edetate disodium is used for chelation therapy instead of edetate calcium disodium. ISMP recommends confirming the diagnosis to help distinguish between the two drugs prior to dispensing and/or administering either drug.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;">Edetate CALCIUM disodium may be confused with etomidate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299251"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220072"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Edetate CALCIUM Disodium may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F6151785"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies; there are no well controlled studies of edetate CALCIUM disodium in pregnant women. Lead is known to cross the placenta in amounts related to maternal plasma levels.  Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment.  Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL.  In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels ≥45 mcg/dL (pregnant women with blood lead levels ≥70 mcg/dL should be considered for chelation regardless of trimester). Alternatives to edetate CALCIUM disodium may be indicated and consultation with experts in lead poisoning and high-risk pregnancy is recommended.  Encephalopathic pregnant women should be chelated regardless of trimester (CDC 2010). </p></div>
<div class="block mopp drugH1Div" id="F53566625"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urinary  output; urinalysis; renal function, hepatic function, serum electrolytes (baseline and daily [severe lead poisoning] or at days 2 and 5 [less severe lead poisoning]); ECG (with IV therapy); blood lead levels (baseline and 7 to 21 days after completing chelation therapy); hemoglobin or hematocrit; iron status; free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes </p></div>
<div class="block pha drugH1Div" id="F164117"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Calcium is displaced by divalent and trivalent heavy metals, forming a nonionizing soluble complex with lead that is excreted in the urine.</p></div>
<div class="block phk drugH1Div" id="F164133"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Chelation of lead: IV: 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Maximum excretion of chelated lead with IV administration: 24 to 48 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM, SubQ: Well absorbed; Oral: &lt;5%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Into extracellular fluid; minimal CSF penetration (~5%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Almost none of the drug is metabolized</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 20 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as metal chelates or unchanged drug); decreased GFR decreases elimination</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038608"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sormetal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Edetato calcico disodico</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Edetal Calcio</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Calcium edetate de sodium serb</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ledclair</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Calcium edetate de sodium | Ledclair</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Edtacal</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bleian</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bleian | Ledcure</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Edetamin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Calcium edetate de sodium serb</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Calcium edetate de sodium serb | Chelagen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7596706">
<a name="7596706"></a>American Academy of Pediatrics Committee on Drugs, “Treatment Guidelines for Lead Exposure in Children,” <i>Pediatrics</i>, 1995, 96(1 Pt 1):155-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/7596706/pubmed" id="7596706" target="_blank">7596706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199720">
<a name="16199720"></a>American Academy of Pediatrics Committee on Environmental Health, “Lead Exposure in Children: Prevention, Detection, and Management,” <i>Pediatrics</i>, 2005, 116(4):1036-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/16199720/pubmed" id="16199720" target="_blank">16199720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18949650">
<a name="18949650"></a>Baxter AJ and Krenzelok EP, “Pediatric Fatality Secondary to ‘EDTA’ Chelation Therapy for Autism,” <i>Clin Toxicol (Phila)</i>, 2008, 46(10):1083-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/18949650/pubmed" id="18949650" target="_blank">18949650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19852620">
<a name="19852620"></a>Bradberry S and Vale A, “A Comparison of Sodium Calcium Edetate (Edetate Calcium Disodium) and Succimer (DMSA) in the Treatment of Inorganic Lead Poisoning,” <i>Clin Toxicol (Phila)</i>, 2009, 47(9):841-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/19852620/pubmed" id="19852620" target="_blank">19852620</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Calcium disodium versenate (edetate calcium disodium) [prescribing information]. Bristol, TN: Luitpold Pharmaceuticals, Inc; July 2009.</div>
</li>
<li>
<div class="reference">
                  Calello DP, Henretig FM. Lead. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw Hill Inc; 2018:1292-1308.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16511441">
<a name="16511441"></a>Centers for Disease Control and Prevention (CDC), “Deaths Associated With Hypocalcemia From Chelation Therapy --Texas, Pennsylvania, and Oregon, 2003-2005,” <i>MMWR Morb Mortal Wkly Rep</i>, 2006, 55(8):204-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/16511441/pubmed" id="16511441" target="_blank">16511441</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>, Atlanta: CDC; 2010.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>, Atlanta: CDC; 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975528">
<a name="17975528"></a>Centers for Disease Control and Prevention (CDC), “Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,” <i>MMWR Recomm Rep</i>, 2007, 56(RR-8):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/17975528/pubmed" id="17975528" target="_blank">17975528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20889734">
<a name="20889734"></a>Chandran L and Cataldo R, “Lead Poisoning: Basics and New Developments,” <i>Pediatr Rev</i>, 2010, 31(10):399-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/20889734/pubmed" id="20889734" target="_blank">20889734</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Council of State and Territorial Epidemiologists (CSTE). Management guidelines for blood lead levels in adults. <a href="https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf" target="_blank">https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf</a>. Updated June 12, 2013. Accessed January 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EdetateCalciumDisodium.1">
<a name="EdetateCalciumDisodium.1"></a>Edetate Calcium Disodium injection, USP [prescribing information]. East Brunswick, NJ: Rising Pharmaceuticals Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17189579">
<a name="17189579"></a>Gracia RC and Snodgrass WR, “Lead Toxicity and Chelation Therapy,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):45-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/17189579/pubmed" id="17189579" target="_blank">17189579</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Howland MA. Antidotes in depth: edetate calcium disodium (CaNa<sub>2</sub>EDTA). In: Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. McGraw Hill Inc; 2018:1315-1318.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17431500">
<a name="17431500"></a>Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. <i>Environ Health Perspect</i>. 2007;115(3):463-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/17431500/pubmed" id="17431500" target="_blank">17431500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19017902">
<a name="19017902"></a>Mitka M, “Chelation Therapy Trials Halted,” <i>JAMA</i>, 2008, 300(19):2236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/19017902/pubmed" id="19017902" target="_blank">19017902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7099793">
<a name="7099793"></a>Moel DI and Kumar K, “Reversible Nephrotic Reactions to a Combined 2,3-Dimercapto-1-propanol and Calcium Disodium Ethylenediaminetetraacetic Acid Regimen in Asymptomatic Children With Elevated Blood Lead Levels,” <i>Pediatrics</i>, 1982, 70(2):259-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/7099793/pubmed" id="7099793" target="_blank">7099793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-125923">
<a name="125923"></a>Morgan JM, “Chelation Therapy in Lead Nephropathy,” <i>South Med J</i>, 1975, 68(8):1001-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/125923/pubmed" id="125923" target="_blank">125923</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nahata MC and Hipple TF, <i>Pediatric Drug Formulations</i>, 3rd ed, Cincinnati, OH: Harvey Whitney Books Co, 1997.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3096624">
<a name="3096624"></a>Osterloh J and Becker CE, “Pharmacokinetics of CaNa<sub>2</sub> EDTA and Chelation of Lead in Renal Failure,” <i>Clin Pharmacol Ther</i>, 1986, 40(6):686-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/3096624/pubmed" id="3096624" target="_blank">3096624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13264 Version 157.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
